Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phosphatidylcholine + piracetam is a combination of two agents commonly used as nootropics to enhance cognitive function. Phosphatidylcholine (often derived from lecithin) is a major component of biological membranes and serves as a precursor for the neurotransmitter acetylcholine, which plays an essential role in memory and learning. Piracetam is a synthetic derivative of gamma-aminobutyric acid (GABA) and was the first compound classified as a nootropic; it is believed to modulate neuronal membrane fluidity, enhance neuroplasticity, improve cerebral blood flow, and facilitate cholinergic neurotransmission. The combination has been studied for its potential synergistic effects on cognition in conditions such as Alzheimer's disease and age-related memory impairment. While animal studies suggest that combining choline or phosphatidylcholine with piracetam may produce greater improvements in memory retention than either agent alone[2], clinical trials in humans have shown mixed results[1]. This combination is generally well tolerated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phosphatidylcholine + piracetam.